← Leaderboards
Stuart R Lessin
Fox Chase Cancer Center
$3,003,785
Attributed
$3,003,785
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $421.8K · FY2006–10$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
Funding mix
By agency
FDA$1,520,557 · 1
NIH$1,483,228 · 2
By mechanism
R01$1,520,557 · 1
P30$1,010,516 · 1
K24$472,712 · 1
Top collaborators
No co-investigators on record.
Most similar at Fox Chase Cancer Center
Same institution · by research overlap
- Mary Beryl Daly$11,073,226
- Andres J Klein-Szanto$7,080,299
- Carolyn Y Fang$18,467,179
- Paul F. Engstrom$18,067,774
- Robert C Young$34,163,223
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchBiopsyCancer Information SystemCancer Registry /ResourceClinical TrialsCurriculumEducation Evaluation /PlanningHealth Science Research PotentialHuman Therapy EvaluationMedical EducationMelanomaNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer VaccineOncologyPathologyPeptide AnalogSkin NeoplasmsTissue Resource /RegistryBiomedical FacilityVector VaccineBiomedical Resource
Grant awards (13)
A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Notrogen Mustard$95,747
R01 · FY2010 · FD · contact PI
A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Notrogen Mustard$304,253
R01 · FY2009 · FD · contact PI
A phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard$421,843
R01 · FY2008 · FD · contact PI
TOPICAL NITROGEN MUSTARD TREATMENT OF MYCOSIS FUNGOIDES*$349,999
R01 · FY2007 · FD · contact PI
TOPICAL NITROGEN MUSTARD TREATMENT OF MYCOSIS FUNGOIDES*$348,715
R01 · FY2006 · FD · contact PI
PATIENT ORIENTED RESEARCH IN CUTANEOUS ONCOLOGY$118,178
K24 · FY2003 · AR
CORE--MELANOMA FACILITY$228,564
P30 · FY2002 · CA
PATIENT ORIENTED RESEARCH IN CUTANEOUS ONCOLOGY$118,178
K24 · FY2002 · AR
CORE--MELANOMA FACILITY$276,694
P30 · FY2001 · CA
CORE--MELANOMA FACILITY$228,564
P30 · FY2001 · CA
PATIENT ORIENTED RESEARCH IN CUTANEOUS ONCOLOGY$118,178
K24 · FY2001 · AR
CORE--MELANOMA FACILITY$276,694
P30 · FY2000 · CA
PATIENT ORIENTED RESEARCH IN CUTANEOUS ONCOLOGY$118,178
K24 · FY2000 · AR